Bococizumab is an experimental monoclonal antibody directed against PCSK9 [1
]. Anti-PCSK9 antibodies are under intense clinical lead scrutiny, as the successors to statins for the treatment of hyperlipidemia and associated atherosclerotic cardiovascular disease. Peptide sequences for this antibody are available from its IMGT link. Based on sequence alignment bococizumab relates to antibody clone L1L3 in patent US8080243
, with SEQ IDs 53 and 54 matching the sequences in the INN record for bococizumab.